G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 109 filers reported holding G1 THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.76 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,475 | +32.0% | 19,082 | +128.1% | 0.00% | – |
| Q2 2023 | $20,809 | +62.4% | 8,364 | +74.5% | 0.00% | – |
| Q1 2023 | $12,814 | -1.4% | 4,793 | +94.5% | 0.00% | – |
| Q4 2022 | $13,000 | -87.6% | 2,464 | -70.8% | 0.00% | – |
| Q3 2022 | $105,000 | +356.5% | 8,427 | +87.0% | 0.00% | – |
| Q2 2022 | $23,000 | -88.1% | 4,507 | +396.4% | 0.00% | – |
| Q1 2022 | $193,000 | +3116.7% | 908 | +62.7% | 0.00% | – |
| Q4 2021 | $6,000 | -71.4% | 558 | -65.9% | 0.00% | – |
| Q3 2021 | $21,000 | -67.2% | 1,636 | -43.5% | 0.00% | – |
| Q2 2021 | $64,000 | -74.4% | 2,896 | -72.2% | 0.00% | -100.0% |
| Q1 2021 | $250,000 | +290.6% | 10,402 | +192.1% | 0.00% | – |
| Q4 2020 | $64,000 | +326.7% | 3,561 | +447.8% | 0.00% | – |
| Q2 2020 | $15,000 | -63.4% | 650 | -82.5% | 0.00% | – |
| Q1 2020 | $41,000 | – | 3,704 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 98,482 | $1,631,000 | 0.60% |
| Opus Point Partners Management, LLC | 20,844 | $346,000 | 0.47% |
| HHLR ADVISORS, LTD. | 949,431 | $15,761,000 | 0.44% |
| Rhenman & Partners Asset Management AB | 212,169 | $3,522,000 | 0.41% |
| Virtus ETF Advisers LLC | 8,654 | $144,000 | 0.31% |
| BB BIOTECH AG | 671,925 | $11,154,000 | 0.28% |
| RA Capital Management | 363,051 | $6,027,000 | 0.26% |
| BDO Wealth Advisors, LLC | 35,234 | $585,000 | 0.17% |
| Birchview Capital, LP | 15,000 | $249,000 | 0.16% |
| SECOR Capital Advisors, LP | 37,205 | $618,000 | 0.13% |